Abstract
OBJECTIVES: The aim of this study is to investigate the effect of type 2 diabetes mellitus (T2DM) on the treatment outcomes of patients with postmenopausal osteoporosis (PMOP). MATERIAL AND METHOD: Thirty-five patients who had been diagnosed as PMOP by lumbar and/or femoral neck bone mineral density screening (BMD) and who had comorbid T2DM were included in the study. Thirty-five patients who had been diagnosed as PMOP but who had no comorbidity including DM constituted the control group. Demographic features, biochemical parameters, femoral and lumbar T scores were all recorded. All patients were treated with bisphosphonate, calcium and vitamin D and the same parameters were evaluated at the end of the first and fifth year. RESULTS: Lumbar T scores and serum osteocalcin levels before treatment were significantly lower in the DM + PMOP group (p < 0,05). At the end of 5 years, despite the lumbar T score having increased, the femoral T score was found to be significantly lower in the DM + PMOP group. In the PMOP group, there was significant improvement in the T scores and serum osteocalcin levels following a 5-year treatment period (p < 0,05). CONCLUSIONS: T2DM has unfavorable effects on treatment prognosis in patients with PMOP. Different risk factors of PMOP which differ in the general population maybe more important when evaluating fracture risk in patients wtih T2DM.